Beside technical validation, the biological validation of that assay was also achieved as we successfully detected shRNAs directed at genes that are currently considered as promising anti-fibrotic targets among the strongest inhibitors of ASMA expression in dermal fibroblasts obtained from 2 different SSc donors. This evidence concerns the gene ACTA1 and systemic sclerosis.